Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Middle Aged | 263 | 2024 | 8284 | 3.590 |
Why?
|
Female | 328 | 2024 | 13136 | 3.460 |
Why?
|
Adult | 237 | 2024 | 7910 | 3.200 |
Why?
|
Diabetes, Gestational | 31 | 2019 | 339 | 3.200 |
Why?
|
Humans | 369 | 2024 | 18430 | 3.190 |
Why?
|
HIV Infections | 37 | 2019 | 695 | 3.060 |
Why?
|
Diabetes Mellitus, Type 2 | 35 | 2019 | 760 | 3.050 |
Why?
|
Breast Neoplasms | 44 | 2017 | 1037 | 3.030 |
Why?
|
Aged | 187 | 2024 | 6417 | 2.720 |
Why?
|
Male | 230 | 2024 | 10440 | 2.630 |
Why?
|
California | 126 | 2024 | 2365 | 2.610 |
Why?
|
Risk Factors | 154 | 2020 | 3449 | 2.550 |
Why?
|
Skin Neoplasms | 9 | 2020 | 64 | 2.410 |
Why?
|
Cohort Studies | 104 | 2022 | 2672 | 1.970 |
Why?
|
Breast Feeding | 11 | 2019 | 133 | 1.810 |
Why?
|
Carcinoma, Basal Cell | 7 | 2020 | 24 | 1.760 |
Why?
|
Risk Assessment | 34 | 2020 | 1143 | 1.740 |
Why?
|
Incidence | 63 | 2020 | 1314 | 1.730 |
Why?
|
Ethnic Groups | 21 | 2016 | 501 | 1.680 |
Why?
|
Obesity | 31 | 2017 | 855 | 1.640 |
Why?
|
Follow-Up Studies | 54 | 2024 | 1269 | 1.600 |
Why?
|
Antiretroviral Therapy, Highly Active | 10 | 2016 | 95 | 1.550 |
Why?
|
Young Adult | 55 | 2024 | 2518 | 1.540 |
Why?
|
Case-Control Studies | 74 | 2016 | 1173 | 1.510 |
Why?
|
Patient Compliance | 12 | 2021 | 318 | 1.470 |
Why?
|
Pregnancy | 55 | 2024 | 1516 | 1.460 |
Why?
|
Adolescent | 74 | 2024 | 3798 | 1.450 |
Why?
|
Aged, 80 and over | 64 | 2017 | 2003 | 1.430 |
Why?
|
Body Mass Index | 46 | 2020 | 974 | 1.420 |
Why?
|
European Continental Ancestry Group | 26 | 2018 | 554 | 1.400 |
Why?
|
Retrospective Studies | 59 | 2024 | 2550 | 1.400 |
Why?
|
Health Maintenance Organizations | 27 | 2013 | 479 | 1.360 |
Why?
|
Neoplasm Recurrence, Local | 15 | 2024 | 249 | 1.350 |
Why?
|
Prospective Studies | 51 | 2024 | 1314 | 1.350 |
Why?
|
Lactation | 9 | 2018 | 50 | 1.350 |
Why?
|
Neoplasms | 21 | 2019 | 457 | 1.340 |
Why?
|
Weight Gain | 13 | 2018 | 181 | 1.320 |
Why?
|
Diabetes Mellitus | 12 | 2017 | 530 | 1.310 |
Why?
|
Continental Population Groups | 20 | 2019 | 315 | 1.300 |
Why?
|
Myocardial Infarction | 17 | 2016 | 249 | 1.270 |
Why?
|
Anti-HIV Agents | 12 | 2016 | 154 | 1.260 |
Why?
|
Carcinoma, Squamous Cell | 7 | 2020 | 55 | 1.230 |
Why?
|
Lung Neoplasms | 15 | 2021 | 259 | 1.160 |
Why?
|
Exercise | 18 | 2024 | 495 | 1.150 |
Why?
|
Hispanic Americans | 21 | 2018 | 428 | 1.080 |
Why?
|
Biomarkers, Tumor | 9 | 2017 | 146 | 1.060 |
Why?
|
Prostatic Neoplasms | 17 | 2017 | 298 | 1.050 |
Why?
|
Adenoma | 5 | 2016 | 100 | 1.030 |
Why?
|
Risk | 27 | 2015 | 552 | 1.020 |
Why?
|
African Americans | 23 | 2017 | 490 | 1.000 |
Why?
|
African Continental Ancestry Group | 12 | 2018 | 166 | 0.970 |
Why?
|
Blood Glucose | 20 | 2015 | 346 | 0.950 |
Why?
|
Motor Activity | 9 | 2014 | 215 | 0.930 |
Why?
|
Longitudinal Studies | 34 | 2019 | 724 | 0.910 |
Why?
|
Proportional Hazards Models | 39 | 2019 | 743 | 0.910 |
Why?
|
Colorectal Neoplasms | 9 | 2016 | 656 | 0.900 |
Why?
|
Registries | 21 | 2017 | 490 | 0.900 |
Why?
|
Odds Ratio | 41 | 2016 | 701 | 0.890 |
Why?
|
Treatment Outcome | 26 | 2024 | 1296 | 0.890 |
Why?
|
Hypoglycemic Agents | 12 | 2015 | 288 | 0.890 |
Why?
|
Age Factors | 31 | 2021 | 965 | 0.880 |
Why?
|
Postpartum Period | 6 | 2024 | 93 | 0.880 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 7 | 2015 | 43 | 0.880 |
Why?
|
Smoking | 24 | 2016 | 494 | 0.870 |
Why?
|
Time Factors | 34 | 2018 | 1136 | 0.850 |
Why?
|
Hypertension | 12 | 2019 | 524 | 0.840 |
Why?
|
Surveys and Questionnaires | 32 | 2019 | 1389 | 0.840 |
Why?
|
Prenatal Exposure Delayed Effects | 7 | 2016 | 159 | 0.840 |
Why?
|
Barrett Esophagus | 11 | 2013 | 114 | 0.810 |
Why?
|
Dementia | 9 | 2019 | 105 | 0.810 |
Why?
|
Health Status | 8 | 2018 | 328 | 0.810 |
Why?
|
Cardiovascular Diseases | 14 | 2016 | 630 | 0.770 |
Why?
|
Melanoma | 3 | 2020 | 37 | 0.770 |
Why?
|
Aging | 10 | 2015 | 165 | 0.770 |
Why?
|
Life Style | 16 | 2019 | 342 | 0.770 |
Why?
|
Puberty | 5 | 2024 | 58 | 0.760 |
Why?
|
Estrogen Replacement Therapy | 10 | 2010 | 104 | 0.740 |
Why?
|
Calcineurin Inhibitors | 1 | 2020 | 2 | 0.740 |
Why?
|
Glucocorticoids | 1 | 2020 | 21 | 0.730 |
Why?
|
Dermatitis, Atopic | 1 | 2020 | 14 | 0.730 |
Why?
|
Antiviral Agents | 3 | 2019 | 95 | 0.730 |
Why?
|
United States | 39 | 2019 | 4164 | 0.720 |
Why?
|
Weight Loss | 4 | 2015 | 321 | 0.690 |
Why?
|
Delivery of Health Care, Integrated | 7 | 2019 | 567 | 0.690 |
Why?
|
SEER Program | 6 | 2017 | 101 | 0.690 |
Why?
|
Logistic Models | 28 | 2021 | 962 | 0.680 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2015 | 55 | 0.670 |
Why?
|
Patient Satisfaction | 6 | 2006 | 232 | 0.670 |
Why?
|
Sex Factors | 20 | 2021 | 661 | 0.650 |
Why?
|
Health Promotion | 5 | 2019 | 294 | 0.650 |
Why?
|
Hypoglycemia | 5 | 2017 | 49 | 0.630 |
Why?
|
Multivariate Analysis | 23 | 2021 | 598 | 0.610 |
Why?
|
Health Status Disparities | 5 | 2017 | 153 | 0.610 |
Why?
|
Lithium | 1 | 2017 | 3 | 0.590 |
Why?
|
Prognosis | 20 | 2017 | 624 | 0.590 |
Why?
|
Fractures, Bone | 8 | 2005 | 91 | 0.590 |
Why?
|
Educational Status | 10 | 2019 | 205 | 0.590 |
Why?
|
Insulin | 12 | 2013 | 208 | 0.580 |
Why?
|
Diabetes Complications | 9 | 2015 | 119 | 0.570 |
Why?
|
Urinary Bladder Neoplasms | 5 | 2024 | 61 | 0.570 |
Why?
|
CD4 Lymphocyte Count | 15 | 2017 | 178 | 0.570 |
Why?
|
Lymph Nodes | 2 | 2016 | 17 | 0.570 |
Why?
|
Carcinoma, Ductal, Breast | 4 | 2015 | 57 | 0.560 |
Why?
|
Gene Expression Profiling | 4 | 2017 | 34 | 0.560 |
Why?
|
Homeodomain Proteins | 2 | 2015 | 16 | 0.560 |
Why?
|
Thiazolidinediones | 7 | 2015 | 54 | 0.560 |
Why?
|
Insulin Resistance | 9 | 2014 | 129 | 0.550 |
Why?
|
Prevalence | 13 | 2017 | 911 | 0.540 |
Why?
|
Physicians, Family | 4 | 2000 | 47 | 0.540 |
Why?
|
Lower Urinary Tract Symptoms | 2 | 2013 | 13 | 0.530 |
Why?
|
Delivery of Health Care | 5 | 2021 | 444 | 0.530 |
Why?
|
Insurance, Health | 5 | 2019 | 217 | 0.520 |
Why?
|
Restless Legs Syndrome | 1 | 2015 | 4 | 0.520 |
Why?
|
Estrogens | 6 | 2012 | 73 | 0.510 |
Why?
|
Infant Formula | 1 | 2015 | 11 | 0.510 |
Why?
|
Cross-Sectional Studies | 20 | 2024 | 1360 | 0.510 |
Why?
|
Coronary Artery Disease | 5 | 2017 | 133 | 0.510 |
Why?
|
Overweight | 4 | 2016 | 276 | 0.510 |
Why?
|
Asthma | 9 | 2009 | 390 | 0.500 |
Why?
|
Child Development | 1 | 2015 | 52 | 0.490 |
Why?
|
Behavior Therapy | 2 | 2015 | 155 | 0.490 |
Why?
|
Hospitalization | 17 | 2016 | 847 | 0.480 |
Why?
|
Mammography | 9 | 2012 | 174 | 0.460 |
Why?
|
Diet | 8 | 2024 | 371 | 0.450 |
Why?
|
Asian Americans | 7 | 2017 | 182 | 0.450 |
Why?
|
Hepatitis C, Chronic | 2 | 2013 | 64 | 0.450 |
Why?
|
Genetic Predisposition to Disease | 9 | 2015 | 414 | 0.450 |
Why?
|
Drug Costs | 1 | 2013 | 40 | 0.440 |
Why?
|
Health Resources | 1 | 2013 | 38 | 0.440 |
Why?
|
Receptors, Interleukin | 1 | 2013 | 4 | 0.440 |
Why?
|
Proton Pump Inhibitors | 2 | 2011 | 25 | 0.440 |
Why?
|
Viral Load | 9 | 2017 | 135 | 0.440 |
Why?
|
Managed Care Programs | 11 | 2017 | 347 | 0.430 |
Why?
|
Substance-Related Disorders | 5 | 2013 | 439 | 0.430 |
Why?
|
Carcinoma in Situ | 2 | 2009 | 17 | 0.430 |
Why?
|
Child | 20 | 2024 | 2571 | 0.430 |
Why?
|
Acquired Immunodeficiency Syndrome | 5 | 2017 | 65 | 0.430 |
Why?
|
Colon | 1 | 2012 | 21 | 0.420 |
Why?
|
Hepatitis C | 3 | 2019 | 65 | 0.420 |
Why?
|
Magnetic Fields | 1 | 2012 | 6 | 0.420 |
Why?
|
Practice Patterns, Physicians' | 6 | 2010 | 350 | 0.410 |
Why?
|
Age Distribution | 14 | 2017 | 261 | 0.410 |
Why?
|
Diabetes Mellitus, Type 1 | 4 | 2017 | 124 | 0.410 |
Why?
|
Drug Utilization Review | 3 | 2007 | 26 | 0.410 |
Why?
|
Schizophrenia | 6 | 2012 | 79 | 0.410 |
Why?
|
Prehypertension | 1 | 2012 | 22 | 0.410 |
Why?
|
Mental Recall | 1 | 2012 | 31 | 0.410 |
Why?
|
Cell Phone | 1 | 2012 | 12 | 0.410 |
Why?
|
Coronary Disease | 7 | 2017 | 185 | 0.400 |
Why?
|
Inflammation | 1 | 2012 | 63 | 0.400 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2009 | 182 | 0.400 |
Why?
|
Adipose Tissue | 7 | 2015 | 60 | 0.400 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2012 | 41 | 0.400 |
Why?
|
Patient Acceptance of Health Care | 4 | 2013 | 407 | 0.390 |
Why?
|
Body Constitution | 7 | 2007 | 39 | 0.390 |
Why?
|
Hip Fractures | 2 | 2010 | 68 | 0.390 |
Why?
|
Stroke | 7 | 2016 | 311 | 0.390 |
Why?
|
Gastroesophageal Reflux | 9 | 2014 | 79 | 0.380 |
Why?
|
Menopause | 3 | 2007 | 72 | 0.380 |
Why?
|
Neoplasm Staging | 15 | 2017 | 337 | 0.380 |
Why?
|
Health | 3 | 2015 | 35 | 0.380 |
Why?
|
Health Behavior | 7 | 2015 | 374 | 0.370 |
Why?
|
Body Weight | 9 | 2018 | 223 | 0.370 |
Why?
|
Risk Reduction Behavior | 5 | 2019 | 114 | 0.370 |
Why?
|
Health Services | 4 | 2013 | 117 | 0.370 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 6 | 2017 | 27 | 0.370 |
Why?
|
Body Composition | 5 | 2013 | 82 | 0.360 |
Why?
|
Neoplasms, Second Primary | 1 | 2010 | 31 | 0.360 |
Why?
|
Social Class | 5 | 2013 | 125 | 0.360 |
Why?
|
Physicians, Women | 2 | 2000 | 10 | 0.360 |
Why?
|
Histamine H2 Antagonists | 1 | 2010 | 13 | 0.350 |
Why?
|
Pregnancy Complications | 5 | 2016 | 193 | 0.350 |
Why?
|
Genome-Wide Association Study | 5 | 2015 | 252 | 0.350 |
Why?
|
Parity | 10 | 2010 | 74 | 0.350 |
Why?
|
Socioeconomic Factors | 14 | 2019 | 673 | 0.350 |
Why?
|
Postmenopause | 8 | 2017 | 267 | 0.340 |
Why?
|
Primary Health Care | 6 | 2021 | 848 | 0.340 |
Why?
|
Polymorphism, Single Nucleotide | 9 | 2016 | 412 | 0.340 |
Why?
|
Women | 2 | 1999 | 12 | 0.340 |
Why?
|
Spouses | 2 | 1999 | 10 | 0.340 |
Why?
|
Infant, Newborn | 13 | 2022 | 872 | 0.330 |
Why?
|
Dyslipidemias | 3 | 2016 | 65 | 0.330 |
Why?
|
Receptors, Estrogen | 5 | 2016 | 58 | 0.320 |
Why?
|
Stress, Psychological | 3 | 2019 | 147 | 0.320 |
Why?
|
Adenocarcinoma | 7 | 2013 | 177 | 0.320 |
Why?
|
Antineoplastic Agents, Hormonal | 4 | 2017 | 65 | 0.310 |
Why?
|
Colonoscopy | 5 | 2016 | 268 | 0.310 |
Why?
|
Survivors | 6 | 2017 | 158 | 0.310 |
Why?
|
Esophageal Neoplasms | 6 | 2013 | 116 | 0.300 |
Why?
|
Lipids | 3 | 2016 | 78 | 0.300 |
Why?
|
Disease Progression | 6 | 2020 | 271 | 0.300 |
Why?
|
Progestins | 4 | 2004 | 28 | 0.300 |
Why?
|
Infant | 13 | 2018 | 1245 | 0.300 |
Why?
|
Genomics | 3 | 2017 | 66 | 0.300 |
Why?
|
Receptor, ErbB-2 | 5 | 2015 | 48 | 0.300 |
Why?
|
Anthropometry | 7 | 2015 | 67 | 0.300 |
Why?
|
Neoplasm Invasiveness | 7 | 2024 | 83 | 0.300 |
Why?
|
Child, Preschool | 12 | 2024 | 1478 | 0.290 |
Why?
|
Coinfection | 2 | 2019 | 30 | 0.290 |
Why?
|
Healthcare Disparities | 4 | 2018 | 211 | 0.290 |
Why?
|
Osteoporosis | 4 | 2017 | 76 | 0.290 |
Why?
|
Pharmacists | 1 | 2007 | 48 | 0.290 |
Why?
|
Confidence Intervals | 13 | 2015 | 253 | 0.280 |
Why?
|
Medication Adherence | 2 | 2010 | 267 | 0.270 |
Why?
|
Health Services Accessibility | 7 | 2016 | 320 | 0.270 |
Why?
|
Analysis of Variance | 8 | 2018 | 167 | 0.270 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2006 | 12 | 0.270 |
Why?
|
Raloxifene Hydrochloride | 1 | 2006 | 13 | 0.270 |
Why?
|
Contraceptives, Oral | 4 | 1998 | 26 | 0.270 |
Why?
|
HIV-1 | 6 | 2012 | 71 | 0.270 |
Why?
|
Aromatase Inhibitors | 2 | 2017 | 35 | 0.270 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2017 | 15 | 0.270 |
Why?
|
Antipsychotic Agents | 3 | 2011 | 57 | 0.270 |
Why?
|
Linear Models | 11 | 2016 | 243 | 0.260 |
Why?
|
Predictive Value of Tests | 8 | 2017 | 365 | 0.260 |
Why?
|
Comorbidity | 10 | 2015 | 619 | 0.260 |
Why?
|
Computational Biology | 2 | 2015 | 28 | 0.260 |
Why?
|
Health Services Research | 7 | 2014 | 264 | 0.260 |
Why?
|
Metabolic Syndrome | 3 | 2010 | 80 | 0.250 |
Why?
|
Cause of Death | 6 | 2017 | 185 | 0.250 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2008 | 392 | 0.250 |
Why?
|
Heart Failure | 5 | 2017 | 398 | 0.250 |
Why?
|
Quality of Life | 7 | 2019 | 529 | 0.250 |
Why?
|
Sex Distribution | 8 | 2017 | 198 | 0.250 |
Why?
|
Marijuana Smoking | 2 | 2003 | 50 | 0.240 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2004 | 6 | 0.240 |
Why?
|
Depression, Postpartum | 1 | 2024 | 18 | 0.240 |
Why?
|
Staphylococcal Infections | 2 | 2015 | 15 | 0.240 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 50 | 0.240 |
Why?
|
Cystitis | 1 | 2004 | 3 | 0.240 |
Why?
|
Mitomycin | 1 | 2024 | 4 | 0.240 |
Why?
|
Isothiocyanates | 1 | 2024 | 8 | 0.240 |
Why?
|
BCG Vaccine | 1 | 2024 | 7 | 0.240 |
Why?
|
Remote Consultation | 1 | 2004 | 11 | 0.240 |
Why?
|
Survival Rate | 5 | 2017 | 269 | 0.240 |
Why?
|
Ambulatory Care | 8 | 2013 | 266 | 0.240 |
Why?
|
Venous Thrombosis | 1 | 2004 | 21 | 0.240 |
Why?
|
Clinical Protocols | 1 | 2004 | 45 | 0.230 |
Why?
|
Hepacivirus | 3 | 2019 | 51 | 0.230 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 3 | 2009 | 116 | 0.230 |
Why?
|
Receptors, Progesterone | 5 | 2015 | 52 | 0.230 |
Why?
|
Menarche | 2 | 2022 | 30 | 0.230 |
Why?
|
Mental Disorders | 3 | 2013 | 295 | 0.230 |
Why?
|
Asian Continental Ancestry Group | 5 | 2016 | 90 | 0.230 |
Why?
|
Adiponectin | 2 | 2014 | 22 | 0.230 |
Why?
|
Quality of Health Care | 4 | 2004 | 347 | 0.230 |
Why?
|
Bone Density | 3 | 2017 | 96 | 0.230 |
Why?
|
Research Design | 3 | 2015 | 402 | 0.220 |
Why?
|
Appointments and Schedules | 2 | 2013 | 34 | 0.220 |
Why?
|
Telemedicine | 2 | 2024 | 184 | 0.220 |
Why?
|
Pregnancy Outcome | 4 | 2009 | 159 | 0.220 |
Why?
|
Pneumonia | 2 | 2017 | 56 | 0.220 |
Why?
|
Glucose Intolerance | 2 | 2015 | 45 | 0.220 |
Why?
|
Epidemiology | 1 | 2003 | 5 | 0.220 |
Why?
|
Women's Health | 7 | 2010 | 207 | 0.220 |
Why?
|
Violence | 1 | 2003 | 30 | 0.220 |
Why?
|
Vitamin D | 2 | 2017 | 80 | 0.220 |
Why?
|
Self Report | 4 | 2019 | 256 | 0.220 |
Why?
|
Language | 2 | 2015 | 52 | 0.210 |
Why?
|
Specialization | 2 | 1999 | 26 | 0.210 |
Why?
|
Genetic Variation | 1 | 2003 | 87 | 0.210 |
Why?
|
Foot Diseases | 1 | 2002 | 2 | 0.210 |
Why?
|
Rhinitis, Allergic, Seasonal | 1 | 2002 | 4 | 0.210 |
Why?
|
Physician-Patient Relations | 3 | 2000 | 197 | 0.210 |
Why?
|
Diabetic Angiopathies | 3 | 2007 | 36 | 0.210 |
Why?
|
Blood Glucose Self-Monitoring | 3 | 2007 | 43 | 0.200 |
Why?
|
Choice Behavior | 2 | 1999 | 48 | 0.200 |
Why?
|
Psychotic Disorders | 3 | 2011 | 47 | 0.200 |
Why?
|
Exercise Test | 3 | 2017 | 45 | 0.200 |
Why?
|
Glucose Tolerance Test | 6 | 2014 | 106 | 0.200 |
Why?
|
Regression Analysis | 12 | 2012 | 319 | 0.200 |
Why?
|
Electronic Mail | 3 | 2019 | 53 | 0.200 |
Why?
|
Drug Therapy, Combination | 6 | 2013 | 119 | 0.200 |
Why?
|
Chronic Disease | 3 | 2009 | 468 | 0.200 |
Why?
|
Adult Children | 2 | 2012 | 8 | 0.200 |
Why?
|
Albuminuria | 1 | 2011 | 41 | 0.200 |
Why?
|
Early Detection of Cancer | 6 | 2021 | 526 | 0.200 |
Why?
|
Prostatectomy | 3 | 2017 | 79 | 0.190 |
Why?
|
Colonic Neoplasms | 5 | 2008 | 157 | 0.190 |
Why?
|
Thyroid Neoplasms | 2 | 2019 | 12 | 0.190 |
Why?
|
Leukocyte Count | 2 | 2012 | 22 | 0.190 |
Why?
|
Lipoproteins, LDL | 3 | 2016 | 15 | 0.190 |
Why?
|
Antioxidants | 3 | 2011 | 40 | 0.190 |
Why?
|
Prochlorperazine | 1 | 2001 | 1 | 0.190 |
Why?
|
Akathisia, Drug-Induced | 1 | 2001 | 1 | 0.190 |
Why?
|
Attitude to Health | 2 | 1999 | 177 | 0.190 |
Why?
|
Multicenter Studies as Topic | 3 | 2018 | 91 | 0.190 |
Why?
|
Antiemetics | 1 | 2001 | 4 | 0.190 |
Why?
|
Precancerous Conditions | 4 | 2009 | 48 | 0.190 |
Why?
|
Interviews as Topic | 8 | 2010 | 327 | 0.190 |
Why?
|
Mass Screening | 5 | 2008 | 690 | 0.190 |
Why?
|
Keratinocytes | 1 | 2020 | 4 | 0.190 |
Why?
|
Anti-Retroviral Agents | 4 | 2015 | 80 | 0.180 |
Why?
|
Biomarkers | 5 | 2014 | 308 | 0.180 |
Why?
|
Estrogen Receptor alpha | 3 | 2015 | 27 | 0.180 |
Why?
|
Pediatric Obesity | 1 | 2022 | 80 | 0.180 |
Why?
|
Health Care Costs | 3 | 2002 | 251 | 0.180 |
Why?
|
Kaplan-Meier Estimate | 7 | 2015 | 131 | 0.180 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2020 | 1 | 0.180 |
Why?
|
Valproic Acid | 1 | 2020 | 4 | 0.180 |
Why?
|
Medicine | 2 | 1999 | 23 | 0.180 |
Why?
|
Skinfold Thickness | 5 | 2015 | 18 | 0.180 |
Why?
|
Patient Selection | 4 | 2015 | 198 | 0.180 |
Why?
|
Patient Education as Topic | 4 | 2014 | 214 | 0.170 |
Why?
|
Caregivers | 2 | 2019 | 126 | 0.170 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2020 | 110 | 0.170 |
Why?
|
Metformin | 3 | 2015 | 61 | 0.170 |
Why?
|
Hepatitis B, Chronic | 3 | 2012 | 27 | 0.170 |
Why?
|
Watchful Waiting | 1 | 2019 | 18 | 0.170 |
Why?
|
Glycated Hemoglobin A | 4 | 2010 | 233 | 0.170 |
Why?
|
Alcohol Drinking | 8 | 2014 | 375 | 0.170 |
Why?
|
Cerebrovascular Disorders | 7 | 2013 | 35 | 0.170 |
Why?
|
Stroke Rehabilitation | 2 | 2009 | 3 | 0.170 |
Why?
|
Puberty, Precocious | 1 | 2019 | 8 | 0.170 |
Why?
|
Rehabilitation Centers | 2 | 2009 | 7 | 0.170 |
Why?
|
Accidental Falls | 5 | 2006 | 40 | 0.170 |
Why?
|
Tamoxifen | 3 | 2009 | 60 | 0.170 |
Why?
|
Glycemic Index | 2 | 2008 | 21 | 0.170 |
Why?
|
Nurse Practitioners | 1 | 1999 | 20 | 0.170 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 3 | 2021 | 199 | 0.170 |
Why?
|
Shoulder Fractures | 3 | 2004 | 4 | 0.170 |
Why?
|
Immunoenzyme Techniques | 3 | 2014 | 20 | 0.170 |
Why?
|
Social Values | 1 | 2019 | 16 | 0.170 |
Why?
|
Pilot Projects | 4 | 2014 | 237 | 0.170 |
Why?
|
RNA, Viral | 3 | 2008 | 64 | 0.170 |
Why?
|
Gynecology | 1 | 1999 | 23 | 0.170 |
Why?
|
Dementia, Vascular | 2 | 2010 | 5 | 0.170 |
Why?
|
Depression | 4 | 2024 | 518 | 0.170 |
Why?
|
RNA, Messenger | 3 | 2014 | 80 | 0.160 |
Why?
|
DNA Repair | 2 | 2008 | 10 | 0.160 |
Why?
|
Physical Fitness | 2 | 2015 | 76 | 0.160 |
Why?
|
Confounding Factors (Epidemiology) | 7 | 2014 | 99 | 0.160 |
Why?
|
Mindfulness | 1 | 2019 | 27 | 0.160 |
Why?
|
Carotid Intima-Media Thickness | 2 | 2015 | 7 | 0.160 |
Why?
|
Anti-Bacterial Agents | 2 | 2006 | 142 | 0.160 |
Why?
|
Medicaid | 5 | 2018 | 211 | 0.160 |
Why?
|
Alzheimer Disease | 2 | 2010 | 43 | 0.160 |
Why?
|
Waist Circumference | 2 | 2015 | 38 | 0.160 |
Why?
|
Genotyping Techniques | 2 | 2015 | 26 | 0.160 |
Why?
|
Sensitivity and Specificity | 8 | 2016 | 321 | 0.160 |
Why?
|
Helicobacter Infections | 2 | 2008 | 22 | 0.160 |
Why?
|
Helicobacter pylori | 2 | 2008 | 24 | 0.160 |
Why?
|
Prostate-Specific Antigen | 3 | 2014 | 77 | 0.150 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2015 | 24 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2011 | 131 | 0.150 |
Why?
|
Sodium Chloride Symporter Inhibitors | 3 | 2005 | 9 | 0.150 |
Why?
|
Reproducibility of Results | 7 | 2015 | 399 | 0.150 |
Why?
|
Occult Blood | 3 | 2016 | 167 | 0.150 |
Why?
|
Coronary Vessels | 1 | 2017 | 15 | 0.150 |
Why?
|
Social Support | 3 | 2012 | 214 | 0.150 |
Why?
|
Calcium | 1 | 2017 | 34 | 0.150 |
Why?
|
Vascular Calcification | 1 | 2017 | 9 | 0.150 |
Why?
|
Transcriptome | 1 | 2017 | 22 | 0.150 |
Why?
|
HIV Protease Inhibitors | 2 | 2011 | 13 | 0.150 |
Why?
|
Prenatal Diagnosis | 1 | 1997 | 18 | 0.150 |
Why?
|
Common Variable Immunodeficiency | 1 | 2017 | 5 | 0.150 |
Why?
|
Contraceptive Agents, Female | 2 | 2012 | 12 | 0.150 |
Why?
|
Cholesterol | 4 | 2012 | 112 | 0.150 |
Why?
|
Forecasting | 1 | 2017 | 80 | 0.150 |
Why?
|
Medical Records | 3 | 2010 | 106 | 0.150 |
Why?
|
Cost Sharing | 1 | 2007 | 40 | 0.140 |
Why?
|
Dietary Fats | 4 | 2009 | 92 | 0.140 |
Why?
|
Preventive Health Services | 2 | 2003 | 166 | 0.140 |
Why?
|
Breast Cancer Lymphedema | 1 | 2016 | 4 | 0.140 |
Why?
|
Neoplasm Grading | 2 | 2014 | 49 | 0.140 |
Why?
|
Metabolic Equivalent | 1 | 2016 | 8 | 0.140 |
Why?
|
Life Expectancy | 1 | 2016 | 33 | 0.140 |
Why?
|
Dideoxynucleosides | 1 | 2016 | 8 | 0.140 |
Why?
|
Pneumococcal Infections | 1 | 2016 | 53 | 0.140 |
Why?
|
Immunoassay | 1 | 2016 | 9 | 0.130 |
Why?
|
Survival Analysis | 5 | 2017 | 226 | 0.130 |
Why?
|
Gene-Environment Interaction | 1 | 2016 | 20 | 0.130 |
Why?
|
Pneumococcal Vaccines | 1 | 2016 | 80 | 0.130 |
Why?
|
Mutation | 2 | 2008 | 132 | 0.130 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2015 | 3 | 0.130 |
Why?
|
Health Care Surveys | 5 | 2004 | 247 | 0.130 |
Why?
|
Staphylococcus aureus | 1 | 2015 | 6 | 0.130 |
Why?
|
Cost of Illness | 2 | 2012 | 100 | 0.130 |
Why?
|
Dietary Fiber | 3 | 2009 | 60 | 0.130 |
Why?
|
Sirolimus | 1 | 2015 | 1 | 0.130 |
Why?
|
Organ Transplantation | 1 | 2015 | 2 | 0.130 |
Why?
|
Transplant Recipients | 1 | 2015 | 4 | 0.130 |
Why?
|
Exercise Therapy | 1 | 2016 | 74 | 0.130 |
Why?
|
Angina Pectoris | 1 | 2015 | 16 | 0.130 |
Why?
|
Nomograms | 1 | 2015 | 13 | 0.130 |
Why?
|
Severity of Illness Index | 4 | 2017 | 476 | 0.130 |
Why?
|
Immunosuppressive Agents | 1 | 2015 | 22 | 0.130 |
Why?
|
Polymorphism, Genetic | 1 | 2015 | 78 | 0.130 |
Why?
|
Cluster Analysis | 1 | 2015 | 96 | 0.130 |
Why?
|
Maternal Exposure | 2 | 2006 | 60 | 0.130 |
Why?
|
Telomere | 1 | 2015 | 19 | 0.130 |
Why?
|
Arteriosclerosis | 1 | 2005 | 20 | 0.130 |
Why?
|
Health Surveys | 5 | 2017 | 269 | 0.130 |
Why?
|
Chromosomes, Human, Pair 15 | 2 | 2016 | 7 | 0.130 |
Why?
|
Epiglottitis | 1 | 1994 | 1 | 0.120 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2017 | 73 | 0.120 |
Why?
|
Carcinoma | 1 | 2015 | 27 | 0.120 |
Why?
|
Mastectomy, Segmental | 2 | 2012 | 23 | 0.120 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2014 | 9 | 0.120 |
Why?
|
Heartburn | 1 | 2014 | 4 | 0.120 |
Why?
|
Carcinoma, Renal Cell | 1 | 1994 | 10 | 0.120 |
Why?
|
Kidney Neoplasms | 1 | 1994 | 16 | 0.120 |
Why?
|
Liver | 1 | 2014 | 33 | 0.120 |
Why?
|
Forearm Injuries | 2 | 2004 | 2 | 0.120 |
Why?
|
Antineoplastic Agents | 1 | 2014 | 65 | 0.120 |
Why?
|
Tibial Fractures | 2 | 2005 | 2 | 0.120 |
Why?
|
Carotid Artery Diseases | 1 | 2014 | 12 | 0.120 |
Why?
|
Preconception Care | 2 | 2014 | 48 | 0.120 |
Why?
|
Anti-Asthmatic Agents | 3 | 2004 | 85 | 0.120 |
Why?
|
Proteinuria | 1 | 2014 | 26 | 0.120 |
Why?
|
Leptin | 1 | 2014 | 30 | 0.120 |
Why?
|
Foot Injuries | 2 | 2004 | 2 | 0.120 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2014 | 23 | 0.120 |
Why?
|
Diabetic Retinopathy | 1 | 2014 | 19 | 0.120 |
Why?
|
Postnatal Care | 1 | 2014 | 22 | 0.120 |
Why?
|
Directive Counseling | 1 | 2014 | 25 | 0.120 |
Why?
|
Quinolones | 2 | 2010 | 4 | 0.120 |
Why?
|
Social Identification | 1 | 2013 | 8 | 0.120 |
Why?
|
Piperazines | 2 | 2010 | 9 | 0.110 |
Why?
|
Telephone | 2 | 2014 | 179 | 0.110 |
Why?
|
Pancreatic Neoplasms | 1 | 2015 | 69 | 0.110 |
Why?
|
Adiposity | 1 | 2014 | 67 | 0.110 |
Why?
|
Insulin, Long-Acting | 1 | 2013 | 12 | 0.110 |
Why?
|
Interferons | 1 | 2013 | 5 | 0.110 |
Why?
|
Philippines | 2 | 2015 | 22 | 0.110 |
Why?
|
Liver Function Tests | 1 | 2013 | 6 | 0.110 |
Why?
|
Ribavirin | 1 | 2013 | 8 | 0.110 |
Why?
|
Financing, Personal | 1 | 2003 | 24 | 0.110 |
Why?
|
Prediabetic State | 1 | 2014 | 53 | 0.110 |
Why?
|
Feeding Behavior | 1 | 2014 | 168 | 0.110 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2013 | 13 | 0.110 |
Why?
|
Hospital Costs | 1 | 2013 | 41 | 0.110 |
Why?
|
Chi-Square Distribution | 5 | 2014 | 160 | 0.110 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 6 | 0.110 |
Why?
|
Subarachnoid Hemorrhage | 1 | 2012 | 4 | 0.110 |
Why?
|
Androstenes | 1 | 2012 | 1 | 0.110 |
Why?
|
Norgestrel | 1 | 2012 | 1 | 0.110 |
Why?
|
Protease Inhibitors | 1 | 2012 | 5 | 0.110 |
Why?
|
Ethinyl Estradiol | 1 | 2012 | 4 | 0.110 |
Why?
|
Desogestrel | 1 | 2012 | 2 | 0.110 |
Why?
|
Acute Coronary Syndrome | 1 | 2012 | 17 | 0.110 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2012 | 1 | 0.110 |
Why?
|
Immunocompromised Host | 1 | 2012 | 20 | 0.110 |
Why?
|
Office Visits | 1 | 2013 | 86 | 0.110 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2012 | 21 | 0.110 |
Why?
|
Genotype | 4 | 2015 | 253 | 0.110 |
Why?
|
Herpesvirus 3, Human | 1 | 2012 | 49 | 0.100 |
Why?
|
Liver Diseases | 1 | 2012 | 25 | 0.100 |
Why?
|
Prenatal Care | 1 | 2014 | 134 | 0.100 |
Why?
|
Diabetic Neuropathies | 1 | 2002 | 13 | 0.100 |
Why?
|
Vitamin A Deficiency | 1 | 2012 | 3 | 0.100 |
Why?
|
Breast | 2 | 2010 | 84 | 0.100 |
Why?
|
Diabetic Nephropathies | 1 | 2002 | 28 | 0.100 |
Why?
|
Monitoring, Ambulatory | 1 | 2012 | 18 | 0.100 |
Why?
|
Prepaid Health Plans | 3 | 2006 | 22 | 0.100 |
Why?
|
Blood Pressure | 4 | 2008 | 310 | 0.100 |
Why?
|
Fasting | 5 | 2014 | 48 | 0.100 |
Why?
|
Blood Pressure Determination | 1 | 2012 | 58 | 0.100 |
Why?
|
Polymerase Chain Reaction | 1 | 2012 | 53 | 0.100 |
Why?
|
Venous Thromboembolism | 1 | 2012 | 52 | 0.100 |
Why?
|
Iron | 2 | 2008 | 17 | 0.100 |
Why?
|
Recurrence | 6 | 2014 | 187 | 0.100 |
Why?
|
Hydrocarbons | 1 | 2011 | 1 | 0.100 |
Why?
|
Polycyclic Aromatic Hydrocarbons | 1 | 2011 | 3 | 0.100 |
Why?
|
Thinness | 1 | 2011 | 29 | 0.100 |
Why?
|
Diseases in Twins | 4 | 1996 | 16 | 0.100 |
Why?
|
Fruit | 2 | 2009 | 79 | 0.100 |
Why?
|
Contrast Media | 1 | 1991 | 9 | 0.100 |
Why?
|
Vegetables | 2 | 2009 | 87 | 0.100 |
Why?
|
Angiopoietin-1 | 1 | 2011 | 2 | 0.100 |
Why?
|
Angiopoietin-2 | 1 | 2011 | 2 | 0.100 |
Why?
|
Receptor, TIE-2 | 1 | 2011 | 2 | 0.100 |
Why?
|
Neovascularization, Physiologic | 1 | 2011 | 3 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2011 | 4 | 0.100 |
Why?
|
High-Throughput Screening Assays | 1 | 2011 | 4 | 0.100 |
Why?
|
Nelfinavir | 1 | 2011 | 4 | 0.100 |
Why?
|
Schizophrenia, Paranoid | 1 | 2011 | 2 | 0.100 |
Why?
|
Docosahexaenoic Acids | 1 | 2011 | 7 | 0.100 |
Why?
|
Molecular Epidemiology | 3 | 2015 | 44 | 0.100 |
Why?
|
Herpes Zoster | 1 | 2012 | 88 | 0.100 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 51 | 0.100 |
Why?
|
Haplotypes | 4 | 2015 | 43 | 0.100 |
Why?
|
Dietary Supplements | 1 | 2011 | 88 | 0.090 |
Why?
|
Poliovirus Vaccine, Inactivated | 2 | 2001 | 21 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 3 | 2021 | 208 | 0.090 |
Why?
|
Occupational Exposure | 1 | 2011 | 67 | 0.090 |
Why?
|
Minority Groups | 1 | 2011 | 105 | 0.090 |
Why?
|
HIV | 1 | 2010 | 26 | 0.090 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2007 | 26 | 0.090 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2010 | 15 | 0.090 |
Why?
|
Cholesterol, HDL | 2 | 2005 | 80 | 0.090 |
Why?
|
Communication | 3 | 2003 | 202 | 0.090 |
Why?
|
Glioma | 1 | 2010 | 5 | 0.090 |
Why?
|
Access to Information | 1 | 2010 | 13 | 0.090 |
Why?
|
Outcome Assessment (Health Care) | 3 | 2009 | 254 | 0.090 |
Why?
|
Carcinoma, Ductal | 1 | 2010 | 5 | 0.090 |
Why?
|
Brain Neoplasms | 1 | 2010 | 15 | 0.090 |
Why?
|
Gastric Acid | 1 | 2010 | 4 | 0.090 |
Why?
|
Referral and Consultation | 3 | 2021 | 180 | 0.090 |
Why?
|
Patients | 1 | 2010 | 38 | 0.090 |
Why?
|
Immunization Schedule | 2 | 2001 | 133 | 0.090 |
Why?
|
Alcoholism | 2 | 2012 | 350 | 0.090 |
Why?
|
Prostatitis | 1 | 2010 | 8 | 0.090 |
Why?
|
Fanconi Syndrome | 1 | 2010 | 4 | 0.090 |
Why?
|
Organophosphonates | 1 | 2010 | 7 | 0.090 |
Why?
|
Adenine | 1 | 2010 | 8 | 0.090 |
Why?
|
Algorithms | 2 | 2011 | 241 | 0.090 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2009 | 4 | 0.090 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2009 | 18 | 0.090 |
Why?
|
Fetal Macrosomia | 2 | 2006 | 27 | 0.090 |
Why?
|
Neoplasm Metastasis | 3 | 2019 | 33 | 0.090 |
Why?
|
Arrhythmias, Cardiac | 2 | 2016 | 32 | 0.090 |
Why?
|
Pharmaceutical Preparations | 1 | 2009 | 11 | 0.090 |
Why?
|
Tobacco Smoke Pollution | 1 | 2010 | 34 | 0.090 |
Why?
|
Parkinson Disease | 1 | 2009 | 15 | 0.090 |
Why?
|
Syphilis | 1 | 2010 | 17 | 0.090 |
Why?
|
Reference Values | 3 | 2015 | 93 | 0.090 |
Why?
|
Erectile Dysfunction | 1 | 2009 | 25 | 0.090 |
Why?
|
Home Care Services | 1 | 2009 | 23 | 0.090 |
Why?
|
Biopsy | 3 | 2017 | 75 | 0.090 |
Why?
|
Suicide, Attempted | 1 | 2010 | 98 | 0.080 |
Why?
|
Sexually Transmitted Diseases | 1 | 2010 | 55 | 0.080 |
Why?
|
Mortality | 3 | 2017 | 123 | 0.080 |
Why?
|
Quality Assurance, Health Care | 1 | 2011 | 188 | 0.080 |
Why?
|
Anticholesteremic Agents | 1 | 2009 | 15 | 0.080 |
Why?
|
Medicare | 3 | 2019 | 214 | 0.080 |
Why?
|
Cytochrome P-450 CYP1A2 | 1 | 2009 | 2 | 0.080 |
Why?
|
Cytochrome P-450 CYP1A1 | 1 | 2009 | 6 | 0.080 |
Why?
|
Gemfibrozil | 1 | 2009 | 5 | 0.080 |
Why?
|
Glomerular Filtration Rate | 1 | 2010 | 157 | 0.080 |
Why?
|
Soy Foods | 1 | 2009 | 10 | 0.080 |
Why?
|
Isoflavones | 1 | 2009 | 14 | 0.080 |
Why?
|
Meat | 1 | 2009 | 27 | 0.080 |
Why?
|
Suicide | 1 | 2010 | 126 | 0.080 |
Why?
|
San Francisco | 5 | 2011 | 68 | 0.080 |
Why?
|
Beer | 1 | 2008 | 9 | 0.080 |
Why?
|
Hypolipidemic Agents | 1 | 2009 | 44 | 0.080 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 7 | 0.080 |
Why?
|
Somatomedins | 1 | 2008 | 5 | 0.080 |
Why?
|
Ferritins | 1 | 2008 | 10 | 0.080 |
Why?
|
Wine | 1 | 2008 | 18 | 0.080 |
Why?
|
Immunoglobulin G | 2 | 2006 | 29 | 0.080 |
Why?
|
Pharmacoepidemiology | 1 | 2008 | 22 | 0.080 |
Why?
|
Hemochromatosis | 1 | 2008 | 9 | 0.080 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2008 | 8 | 0.080 |
Why?
|
Bayes Theorem | 1 | 2008 | 69 | 0.080 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2008 | 9 | 0.080 |
Why?
|
Rectal Neoplasms | 2 | 1995 | 67 | 0.080 |
Why?
|
Body Fat Distribution | 1 | 2008 | 5 | 0.080 |
Why?
|
Reproduction | 1 | 2008 | 12 | 0.080 |
Why?
|
Brain Ischemia | 2 | 1998 | 37 | 0.080 |
Why?
|
Androgens | 1 | 2008 | 13 | 0.080 |
Why?
|
Kidney Diseases | 2 | 2011 | 55 | 0.080 |
Why?
|
Intra-Abdominal Fat | 1 | 2008 | 15 | 0.080 |
Why?
|
Membrane Proteins | 1 | 2008 | 40 | 0.080 |
Why?
|
Data Interpretation, Statistical | 1 | 2008 | 83 | 0.080 |
Why?
|
Methylphenidate | 1 | 2007 | 4 | 0.080 |
Why?
|
Sentinel Surveillance | 1 | 2007 | 14 | 0.080 |
Why?
|
Environment | 2 | 1999 | 51 | 0.080 |
Why?
|
Drug Prescriptions | 2 | 2007 | 157 | 0.080 |
Why?
|
Reproductive History | 1 | 2007 | 18 | 0.080 |
Why?
|
Twins | 4 | 1996 | 13 | 0.070 |
Why?
|
Population Surveillance | 2 | 2017 | 271 | 0.070 |
Why?
|
Poisson Distribution | 3 | 2011 | 94 | 0.070 |
Why?
|
Serotonin Uptake Inhibitors | 1 | 2008 | 74 | 0.070 |
Why?
|
Colonic Polyps | 1 | 2007 | 35 | 0.070 |
Why?
|
Age of Onset | 3 | 2016 | 82 | 0.070 |
Why?
|
Breast Diseases | 1 | 2007 | 17 | 0.070 |
Why?
|
Cholecystectomy | 1 | 1987 | 3 | 0.070 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2007 | 25 | 0.070 |
Why?
|
Abdominal Fat | 1 | 2007 | 15 | 0.070 |
Why?
|
Prostatic Hyperplasia | 3 | 1992 | 24 | 0.070 |
Why?
|
Models, Statistical | 2 | 1999 | 185 | 0.070 |
Why?
|
Leisure Activities | 3 | 2006 | 33 | 0.070 |
Why?
|
Functional Laterality | 2 | 2004 | 3 | 0.070 |
Why?
|
Mental Health | 2 | 2024 | 168 | 0.070 |
Why?
|
Principal Component Analysis | 3 | 2015 | 23 | 0.070 |
Why?
|
Acute Disease | 2 | 2000 | 144 | 0.070 |
Why?
|
Homocysteine | 1 | 2007 | 13 | 0.070 |
Why?
|
Herpesvirus 2, Human | 1 | 2006 | 4 | 0.070 |
Why?
|
Herpes Simplex | 1 | 2006 | 6 | 0.070 |
Why?
|
Hyperbilirubinemia | 1 | 2006 | 9 | 0.070 |
Why?
|
Surgical Procedures, Operative | 1 | 2006 | 17 | 0.070 |
Why?
|
Medical Audit | 3 | 2010 | 41 | 0.070 |
Why?
|
Hormone Replacement Therapy | 2 | 2004 | 28 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 150 | 0.070 |
Why?
|
Hyperbilirubinemia, Neonatal | 1 | 2006 | 16 | 0.070 |
Why?
|
Ulna Fractures | 2 | 2004 | 2 | 0.070 |
Why?
|
Length of Stay | 4 | 2009 | 183 | 0.070 |
Why?
|
Radius Fractures | 2 | 2004 | 4 | 0.070 |
Why?
|
Deoxycytidine | 1 | 2006 | 7 | 0.070 |
Why?
|
Apolipoproteins E | 1 | 2005 | 10 | 0.070 |
Why?
|
Pelvis | 1 | 2005 | 3 | 0.070 |
Why?
|
Drug Information Services | 1 | 2005 | 3 | 0.070 |
Why?
|
Medication Errors | 1 | 2005 | 7 | 0.070 |
Why?
|
Hemorrhage | 1 | 2006 | 63 | 0.070 |
Why?
|
Fibula | 1 | 2005 | 1 | 0.070 |
Why?
|
Depressive Disorder | 1 | 2008 | 231 | 0.070 |
Why?
|
Diuretics | 3 | 2008 | 17 | 0.070 |
Why?
|
Epidemiologic Studies | 2 | 2002 | 32 | 0.060 |
Why?
|
Environment Design | 1 | 2006 | 68 | 0.060 |
Why?
|
Antibodies, Protozoan | 1 | 2005 | 3 | 0.060 |
Why?
|
Toxoplasma | 1 | 2005 | 3 | 0.060 |
Why?
|
Toxoplasmosis | 1 | 2005 | 4 | 0.060 |
Why?
|
Warfarin | 1 | 2006 | 73 | 0.060 |
Why?
|
Pregnancy Complications, Parasitic | 1 | 2005 | 4 | 0.060 |
Why?
|
Medical Records Systems, Computerized | 1 | 2005 | 95 | 0.060 |
Why?
|
Anticoagulants | 1 | 2006 | 125 | 0.060 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2006 | 142 | 0.060 |
Why?
|
Observational Studies as Topic | 1 | 2015 | 49 | 0.060 |
Why?
|
Patient Admission | 2 | 2002 | 76 | 0.060 |
Why?
|
Remission Induction | 1 | 2014 | 25 | 0.060 |
Why?
|
Diet Surveys | 2 | 2009 | 58 | 0.060 |
Why?
|
Adaptation, Psychological | 2 | 2019 | 82 | 0.060 |
Why?
|
Prothrombin | 1 | 2004 | 2 | 0.060 |
Why?
|
Factor V | 1 | 2004 | 5 | 0.060 |
Why?
|
Utah | 3 | 2014 | 33 | 0.060 |
Why?
|
Cross-Over Studies | 2 | 2014 | 45 | 0.060 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2024 | 8 | 0.060 |
Why?
|
Cultural Diversity | 1 | 2004 | 17 | 0.060 |
Why?
|
Sexual Maturation | 1 | 2024 | 8 | 0.060 |
Why?
|
Adjuvants, Immunologic | 1 | 2024 | 15 | 0.060 |
Why?
|
Hawaii | 1 | 2024 | 45 | 0.060 |
Why?
|
Central Nervous System Stimulants | 2 | 2007 | 29 | 0.060 |
Why?
|
Vaccination | 2 | 2016 | 674 | 0.060 |
Why?
|
Statistics, Nonparametric | 2 | 2001 | 51 | 0.060 |
Why?
|
Drug Administration Schedule | 3 | 2010 | 100 | 0.060 |
Why?
|
Receptors, Nicotinic | 2 | 2016 | 9 | 0.060 |
Why?
|
Sulfonylurea Compounds | 2 | 2007 | 28 | 0.060 |
Why?
|
Clinical Competence | 2 | 2004 | 108 | 0.060 |
Why?
|
Pelvic Bones | 1 | 2003 | 5 | 0.060 |
Why?
|
Nerve Tissue Proteins | 2 | 2016 | 21 | 0.060 |
Why?
|
Anxiety | 1 | 2024 | 156 | 0.060 |
Why?
|
Databases, Factual | 3 | 2010 | 327 | 0.060 |
Why?
|
Accidents, Traffic | 1 | 2003 | 15 | 0.050 |
Why?
|
Triglycerides | 3 | 2009 | 87 | 0.050 |
Why?
|
Oxidants, Photochemical | 1 | 2002 | 2 | 0.050 |
Why?
|
Carbon Monoxide | 1 | 2002 | 13 | 0.050 |
Why?
|
Epidemiologic Methods | 3 | 2009 | 87 | 0.050 |
Why?
|
Nitrogen Dioxide | 1 | 2002 | 13 | 0.050 |
Why?
|
Ozone | 1 | 2002 | 11 | 0.050 |
Why?
|
Infectious Disease Transmission, Vertical | 2 | 2006 | 22 | 0.050 |
Why?
|
Myocardial Ischemia | 1 | 2002 | 24 | 0.050 |
Why?
|
Ventricular Fibrillation | 1 | 2002 | 4 | 0.050 |
Why?
|
Menstrual Cycle | 1 | 2002 | 8 | 0.050 |
Why?
|
Tachycardia, Ventricular | 1 | 2002 | 6 | 0.050 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2014 | 129 | 0.050 |
Why?
|
Oceanic Ancestry Group | 1 | 2012 | 33 | 0.050 |
Why?
|
Vasectomy | 2 | 1993 | 3 | 0.050 |
Why?
|
Flatfoot | 1 | 2002 | 1 | 0.050 |
Why?
|
Diabetic Foot | 1 | 2002 | 3 | 0.050 |
Why?
|
Multiphasic Screening | 3 | 2010 | 10 | 0.050 |
Why?
|
Environmental Health | 1 | 2002 | 8 | 0.050 |
Why?
|
Public Health | 1 | 2003 | 82 | 0.050 |
Why?
|
Bariatric Surgery | 1 | 2014 | 130 | 0.050 |
Why?
|
Sigmoidoscopy | 3 | 2007 | 67 | 0.050 |
Why?
|
Air Pollutants | 1 | 2002 | 52 | 0.050 |
Why?
|
Direct Service Costs | 2 | 2000 | 10 | 0.050 |
Why?
|
Diet, Fat-Restricted | 2 | 2014 | 38 | 0.050 |
Why?
|
China | 2 | 2012 | 130 | 0.050 |
Why?
|
Cerebral Hemorrhage | 2 | 1998 | 14 | 0.050 |
Why?
|
Anti-Inflammatory Agents | 2 | 2004 | 25 | 0.050 |
Why?
|
Anus Neoplasms | 2 | 2012 | 26 | 0.050 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2015 | 17 | 0.050 |
Why?
|
Computer Simulation | 2 | 1999 | 85 | 0.050 |
Why?
|
Esophagoscopy | 2 | 2013 | 19 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2019 | 120 | 0.050 |
Why?
|
Homeostasis | 2 | 2014 | 11 | 0.050 |
Why?
|
Infusions, Intravenous | 1 | 2001 | 10 | 0.050 |
Why?
|
Data Collection | 2 | 2007 | 275 | 0.050 |
Why?
|
Academic Medical Centers | 1 | 2021 | 31 | 0.050 |
Why?
|
Double-Blind Method | 1 | 2001 | 165 | 0.050 |
Why?
|
Hypercholesterolemia | 1 | 2000 | 33 | 0.050 |
Why?
|
Electronic Health Records | 2 | 2017 | 747 | 0.050 |
Why?
|
Insurance Coverage | 1 | 2011 | 136 | 0.050 |
Why?
|
Aripiprazole | 2 | 2010 | 5 | 0.040 |
Why?
|
Vitamin E | 2 | 2011 | 20 | 0.040 |
Why?
|
Ascorbic Acid | 2 | 2011 | 19 | 0.040 |
Why?
|
Diagnosis-Related Groups | 1 | 2000 | 27 | 0.040 |
Why?
|
Bipolar Disorder | 2 | 2010 | 63 | 0.040 |
Why?
|
Parents | 1 | 2003 | 309 | 0.040 |
Why?
|
Matched-Pair Analysis | 1 | 2019 | 11 | 0.040 |
Why?
|
Accelerometry | 1 | 2019 | 37 | 0.040 |
Why?
|
Health Facility Environment | 1 | 1999 | 2 | 0.040 |
Why?
|
Economics, Medical | 1 | 1999 | 6 | 0.040 |
Why?
|
Primary Prevention | 1 | 2000 | 79 | 0.040 |
Why?
|
Sustained Virologic Response | 1 | 2019 | 17 | 0.040 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2009 | 27 | 0.040 |
Why?
|
Occupations | 1 | 1999 | 16 | 0.040 |
Why?
|
Child Health Services | 2 | 2001 | 129 | 0.040 |
Why?
|
Insurance Claim Review | 1 | 2009 | 70 | 0.040 |
Why?
|
Climacteric | 1 | 1999 | 2 | 0.040 |
Why?
|
Propensity Score | 1 | 2019 | 94 | 0.040 |
Why?
|
Child of Impaired Parents | 2 | 2011 | 33 | 0.040 |
Why?
|
Deductibles and Coinsurance | 1 | 2009 | 31 | 0.040 |
Why?
|
Program Development | 1 | 2019 | 81 | 0.040 |
Why?
|
Amphetamine | 1 | 1998 | 2 | 0.040 |
Why?
|
Narcotics | 1 | 1998 | 7 | 0.040 |
Why?
|
Cocaine | 1 | 1998 | 6 | 0.040 |
Why?
|
Food | 1 | 1998 | 31 | 0.040 |
Why?
|
Meditation | 1 | 2019 | 20 | 0.040 |
Why?
|
Drug Interactions | 2 | 2011 | 20 | 0.040 |
Why?
|
Hot Flashes | 1 | 1999 | 39 | 0.040 |
Why?
|
Geography | 2 | 2008 | 41 | 0.040 |
Why?
|
Levonorgestrel | 1 | 1998 | 5 | 0.040 |
Why?
|
Health Expenditures | 1 | 2009 | 82 | 0.040 |
Why?
|
Fertility | 1 | 1998 | 10 | 0.040 |
Why?
|
Sex Characteristics | 2 | 2015 | 70 | 0.040 |
Why?
|
Caffeine | 1 | 1998 | 18 | 0.040 |
Why?
|
Mastectomy | 1 | 2017 | 39 | 0.040 |
Why?
|
Coronary Angiography | 1 | 2017 | 22 | 0.040 |
Why?
|
Bias | 2 | 2008 | 111 | 0.040 |
Why?
|
Emergency Medical Services | 1 | 1997 | 47 | 0.040 |
Why?
|
Nurse-Patient Relations | 1 | 1997 | 8 | 0.040 |
Why?
|
Health Status Indicators | 1 | 2007 | 71 | 0.040 |
Why?
|
Cholesterol, LDL | 2 | 2009 | 125 | 0.040 |
Why?
|
Outcome and Process Assessment (Health Care) | 1 | 2007 | 110 | 0.040 |
Why?
|
Premenopause | 1 | 2017 | 27 | 0.040 |
Why?
|
Mothers | 1 | 2018 | 110 | 0.040 |
Why?
|
Twins, Monozygotic | 3 | 1993 | 12 | 0.040 |
Why?
|
Diphosphonates | 1 | 2017 | 62 | 0.040 |
Why?
|
Serogroup | 1 | 2016 | 10 | 0.040 |
Why?
|
Non-ST Elevated Myocardial Infarction | 1 | 2016 | 8 | 0.040 |
Why?
|
Streptococcus pneumoniae | 1 | 2016 | 25 | 0.040 |
Why?
|
Hospitals | 1 | 1997 | 80 | 0.030 |
Why?
|
Calcium Oxalate | 1 | 1996 | 2 | 0.030 |
Why?
|
Diet, Protein-Restricted | 1 | 1996 | 2 | 0.030 |
Why?
|
Kidney Calculi | 1 | 1996 | 6 | 0.030 |
Why?
|
Animals | 2 | 2009 | 261 | 0.030 |
Why?
|
Acyclovir | 1 | 1996 | 5 | 0.030 |
Why?
|
Vaccines, Conjugate | 1 | 2016 | 66 | 0.030 |
Why?
|
Facial Paralysis | 1 | 1996 | 2 | 0.030 |
Why?
|
Prednisone | 1 | 1996 | 5 | 0.030 |
Why?
|
Lipoproteins, HDL | 1 | 2016 | 7 | 0.030 |
Why?
|
Protective Factors | 1 | 2016 | 33 | 0.030 |
Why?
|
Goals | 1 | 2016 | 33 | 0.030 |
Why?
|
Self Care | 1 | 2007 | 175 | 0.030 |
Why?
|
Heart Valve Diseases | 1 | 2016 | 20 | 0.030 |
Why?
|
Seroepidemiologic Studies | 2 | 2006 | 20 | 0.030 |
Why?
|
Washington | 2 | 2012 | 388 | 0.030 |
Why?
|
Genes, Modifier | 1 | 2016 | 3 | 0.030 |
Why?
|
Heart Diseases | 1 | 2016 | 77 | 0.030 |
Why?
|
Lipid Metabolism | 1 | 2015 | 13 | 0.030 |
Why?
|
Indians, North American | 1 | 2016 | 50 | 0.030 |
Why?
|
Larynx | 1 | 1995 | 1 | 0.030 |
Why?
|
Mouth | 1 | 1995 | 1 | 0.030 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 1995 | 1 | 0.030 |
Why?
|
Paranasal Sinuses | 1 | 1995 | 1 | 0.030 |
Why?
|
Pharyngeal Neoplasms | 1 | 1995 | 2 | 0.030 |
Why?
|
Pharynx | 1 | 1995 | 3 | 0.030 |
Why?
|
Laryngeal Neoplasms | 1 | 1995 | 2 | 0.030 |
Why?
|
Pregnancy Complications, Cardiovascular | 2 | 2011 | 27 | 0.030 |
Why?
|
Mouth Neoplasms | 1 | 1995 | 9 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2015 | 9 | 0.030 |
Why?
|
Bereavement | 1 | 1995 | 4 | 0.030 |
Why?
|
INDEL Mutation | 1 | 2015 | 7 | 0.030 |
Why?
|
Automation | 1 | 2015 | 24 | 0.030 |
Why?
|
Osmolar Concentration | 2 | 1993 | 8 | 0.030 |
Why?
|
Quality Control | 1 | 2015 | 48 | 0.030 |
Why?
|
Abdomen | 1 | 2005 | 21 | 0.030 |
Why?
|
Pedigree | 1 | 2015 | 58 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2015 | 20 | 0.030 |
Why?
|
Self Disclosure | 1 | 1995 | 24 | 0.030 |
Why?
|
Quantitative Trait Loci | 1 | 2015 | 38 | 0.030 |
Why?
|
Feces | 1 | 2016 | 88 | 0.030 |
Why?
|
Alleles | 1 | 2015 | 95 | 0.030 |
Why?
|
Phylogeny | 1 | 2015 | 14 | 0.030 |
Why?
|
Urinalysis | 1 | 1995 | 9 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2015 | 23 | 0.030 |
Why?
|
Tracheotomy | 1 | 1994 | 2 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2016 | 162 | 0.030 |
Why?
|
Palpation | 2 | 1991 | 10 | 0.030 |
Why?
|
Intubation, Intratracheal | 1 | 1994 | 6 | 0.030 |
Why?
|
Social Environment | 1 | 1995 | 90 | 0.030 |
Why?
|
Citrus | 1 | 2014 | 3 | 0.030 |
Why?
|
Lycopersicon esculentum | 1 | 2014 | 4 | 0.030 |
Why?
|
Tea | 1 | 2014 | 8 | 0.030 |
Why?
|
Diet, High-Fat | 1 | 2014 | 6 | 0.030 |
Why?
|
Calcium, Dietary | 2 | 2004 | 28 | 0.030 |
Why?
|
Hydrochlorothiazide | 1 | 1994 | 5 | 0.030 |
Why?
|
Carbonated Beverages | 1 | 2014 | 14 | 0.030 |
Why?
|
Michigan | 2 | 2006 | 26 | 0.030 |
Why?
|
Molecular Targeted Therapy | 1 | 2014 | 7 | 0.030 |
Why?
|
Head and Neck Neoplasms | 1 | 2014 | 6 | 0.030 |
Why?
|
Trastuzumab | 1 | 2014 | 17 | 0.030 |
Why?
|
Lipoprotein(a) | 1 | 1994 | 7 | 0.030 |
Why?
|
Fatty Acids, Nonesterified | 1 | 2014 | 12 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2014 | 57 | 0.030 |
Why?
|
Lipoproteins | 1 | 2014 | 14 | 0.030 |
Why?
|
Absorptiometry, Photon | 2 | 2008 | 52 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2014 | 46 | 0.030 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2014 | 26 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2014 | 40 | 0.030 |
Why?
|
Hyperinsulinism | 1 | 1993 | 9 | 0.030 |
Why?
|
Insulin Glargine | 1 | 2013 | 9 | 0.030 |
Why?
|
Decision Support Techniques | 1 | 1994 | 95 | 0.030 |
Why?
|
Eating | 1 | 1993 | 38 | 0.030 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2003 | 6 | 0.030 |
Why?
|
Administration, Inhalation | 2 | 2004 | 37 | 0.030 |
Why?
|
Tumor Burden | 1 | 2013 | 20 | 0.030 |
Why?
|
Psychometrics | 1 | 2013 | 124 | 0.030 |
Why?
|
Necrosis | 1 | 2012 | 3 | 0.030 |
Why?
|
Hematologic Neoplasms | 1 | 2012 | 8 | 0.030 |
Why?
|
Tennessee | 1 | 2012 | 6 | 0.030 |
Why?
|
Arteries | 1 | 2012 | 8 | 0.030 |
Why?
|
Twins, Dizygotic | 2 | 1990 | 8 | 0.030 |
Why?
|
Health Education | 1 | 2003 | 115 | 0.030 |
Why?
|
Social Networking | 1 | 2012 | 20 | 0.030 |
Why?
|
Drug Combinations | 1 | 2012 | 43 | 0.030 |
Why?
|
Thromboembolism | 1 | 2012 | 34 | 0.030 |
Why?
|
Family Characteristics | 1 | 2012 | 54 | 0.030 |
Why?
|
Amputation | 1 | 2002 | 11 | 0.030 |
Why?
|
Environmental Exposure | 2 | 2009 | 115 | 0.030 |
Why?
|
Pregnancy Trimester, Second | 1 | 2012 | 26 | 0.030 |
Why?
|
International Cooperation | 1 | 2012 | 17 | 0.030 |
Why?
|
Infant Food | 1 | 2011 | 8 | 0.030 |
Why?
|
Virus Replication | 1 | 2011 | 12 | 0.030 |
Why?
|
Bottle Feeding | 1 | 2011 | 8 | 0.030 |
Why?
|
Hospital Mortality | 1 | 2012 | 150 | 0.020 |
Why?
|
Far East | 1 | 2011 | 6 | 0.020 |
Why?
|
Carotenoids | 1 | 2011 | 29 | 0.020 |
Why?
|
Cost Control | 1 | 1991 | 25 | 0.020 |
Why?
|
Genome, Human | 1 | 2011 | 42 | 0.020 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2011 | 2 | 0.020 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 6 | 0.020 |
Why?
|
Cytochrome P-450 CYP2C19 | 1 | 2011 | 4 | 0.020 |
Why?
|
Pediatrics | 2 | 2004 | 166 | 0.020 |
Why?
|
Panic Disorder | 1 | 2010 | 6 | 0.020 |
Why?
|
Diagnosis, Dual (Psychiatry) | 1 | 2010 | 28 | 0.020 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2010 | 4 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2010 | 12 | 0.020 |
Why?
|
Kidney Failure, Chronic | 1 | 2002 | 151 | 0.020 |
Why?
|
Pathology, Clinical | 1 | 2010 | 14 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2010 | 26 | 0.020 |
Why?
|
Cognition Disorders | 1 | 2010 | 32 | 0.020 |
Why?
|
Blood Proteins | 1 | 1990 | 3 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2010 | 23 | 0.020 |
Why?
|
Laboratories | 1 | 2010 | 23 | 0.020 |
Why?
|
Phenotype | 2 | 2005 | 148 | 0.020 |
Why?
|
Uric Acid | 1 | 1990 | 11 | 0.020 |
Why?
|
Respiratory Function Tests | 1 | 1990 | 32 | 0.020 |
Why?
|
Databases as Topic | 1 | 2010 | 22 | 0.020 |
Why?
|
Mammary Glands, Human | 1 | 2010 | 8 | 0.020 |
Why?
|
Drug Utilization | 2 | 2004 | 134 | 0.020 |
Why?
|
Diet Records | 1 | 2010 | 36 | 0.020 |
Why?
|
Heart Rate | 1 | 1990 | 40 | 0.020 |
Why?
|
Estrogen Antagonists | 1 | 2010 | 3 | 0.020 |
Why?
|
Massachusetts | 1 | 2010 | 99 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2010 | 22 | 0.020 |
Why?
|
Carcinogenicity Tests | 1 | 2009 | 3 | 0.020 |
Why?
|
Carcinogens | 1 | 2009 | 4 | 0.020 |
Why?
|
Tenofovir | 1 | 2010 | 18 | 0.020 |
Why?
|
Treatment Failure | 1 | 2010 | 36 | 0.020 |
Why?
|
Pneumonia, Pneumocystis | 1 | 1989 | 5 | 0.020 |
Why?
|
Opportunistic Infections | 1 | 1989 | 8 | 0.020 |
Why?
|
Sunlight | 1 | 2009 | 16 | 0.020 |
Why?
|
Likelihood Functions | 1 | 2010 | 48 | 0.020 |
Why?
|
Obesity, Morbid | 1 | 2011 | 120 | 0.020 |
Why?
|
Sarcoma, Kaposi | 1 | 1989 | 13 | 0.020 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2009 | 18 | 0.020 |
Why?
|
Creatinine | 1 | 2010 | 65 | 0.020 |
Why?
|
Gonadal Steroid Hormones | 1 | 2009 | 33 | 0.020 |
Why?
|
Thiazoles | 1 | 2009 | 9 | 0.020 |
Why?
|
Clozapine | 1 | 2009 | 5 | 0.020 |
Why?
|
Patient Discharge | 2 | 2005 | 153 | 0.020 |
Why?
|
Dietary Sucrose | 1 | 2009 | 12 | 0.020 |
Why?
|
Benzodiazepines | 1 | 2009 | 26 | 0.020 |
Why?
|
Depressive Disorder, Major | 1 | 2010 | 127 | 0.020 |
Why?
|
Occupational Health Services | 1 | 2009 | 16 | 0.020 |
Why?
|
Linkage Disequilibrium | 1 | 2009 | 39 | 0.020 |
Why?
|
Workplace | 1 | 2009 | 36 | 0.020 |
Why?
|
Small-Area Analysis | 1 | 2009 | 4 | 0.020 |
Why?
|
Trans Fatty Acids | 1 | 2009 | 4 | 0.020 |
Why?
|
Cooking | 1 | 2009 | 17 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2008 | 5 | 0.020 |
Why?
|
DNA Ligase ATP | 1 | 2008 | 2 | 0.020 |
Why?
|
DNA Ligases | 1 | 2008 | 2 | 0.020 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2008 | 2 | 0.020 |
Why?
|
Endonucleases | 1 | 2008 | 3 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2008 | 11 | 0.020 |
Why?
|
Computer-Assisted Instruction | 1 | 2008 | 11 | 0.020 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2009 | 22 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Protein 2 | 1 | 2008 | 2 | 0.020 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2008 | 3 | 0.020 |
Why?
|
Iron, Dietary | 1 | 2008 | 7 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2008 | 11 | 0.020 |
Why?
|
Transcription Factors | 1 | 2008 | 20 | 0.020 |
Why?
|
Self-Assessment | 1 | 2008 | 17 | 0.020 |
Why?
|
Ligands | 1 | 2008 | 6 | 0.020 |
Why?
|
Outpatients | 1 | 2009 | 111 | 0.020 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2008 | 17 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2008 | 31 | 0.020 |
Why?
|
Antiprotozoal Agents | 1 | 2008 | 2 | 0.020 |
Why?
|
Furosemide | 1 | 2008 | 2 | 0.020 |
Why?
|
Griseofulvin | 1 | 2008 | 2 | 0.020 |
Why?
|
Metronidazole | 1 | 2008 | 4 | 0.020 |
Why?
|
Mental Health Services | 1 | 2010 | 161 | 0.020 |
Why?
|
Sodium, Dietary | 1 | 1988 | 9 | 0.020 |
Why?
|
Antifungal Agents | 1 | 2008 | 4 | 0.020 |
Why?
|
beta Carotene | 1 | 2008 | 17 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2009 | 96 | 0.020 |
Why?
|
Hemochromatosis Protein | 1 | 2008 | 8 | 0.020 |
Why?
|
Homozygote | 1 | 2008 | 14 | 0.020 |
Why?
|
Heterozygote | 1 | 2008 | 29 | 0.020 |
Why?
|
Virilism | 1 | 2008 | 1 | 0.020 |
Why?
|
Subcutaneous Fat, Abdominal | 1 | 2008 | 4 | 0.020 |
Why?
|
Body Weights and Measures | 1 | 2008 | 13 | 0.020 |
Why?
|
Lovastatin | 1 | 2008 | 7 | 0.020 |
Why?
|
Amphetamines | 1 | 2007 | 2 | 0.020 |
Why?
|
Leukemia, Lymphoid | 1 | 2007 | 2 | 0.020 |
Why?
|
Pemoline | 1 | 2007 | 2 | 0.020 |
Why?
|
Clinical Pharmacy Information Systems | 1 | 2007 | 11 | 0.020 |
Why?
|
Simvastatin | 1 | 2008 | 11 | 0.020 |
Why?
|
Men's Health | 1 | 2007 | 20 | 0.020 |
Why?
|
Antigens, Bacterial | 1 | 2007 | 8 | 0.020 |
Why?
|
Bacterial Proteins | 1 | 2007 | 18 | 0.020 |
Why?
|
Antibodies, Bacterial | 1 | 2007 | 38 | 0.020 |
Why?
|
Demography | 1 | 2007 | 108 | 0.020 |
Why?
|
Thigh | 1 | 2007 | 11 | 0.020 |
Why?
|
Waist-Hip Ratio | 1 | 2007 | 23 | 0.020 |
Why?
|
Weaning | 1 | 2007 | 6 | 0.020 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 1 | 2007 | 4 | 0.020 |
Why?
|
Education, Medical, Continuing | 1 | 2007 | 31 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 68 | 0.020 |
Why?
|
Pregnancy Trimester, Third | 1 | 2007 | 17 | 0.020 |
Why?
|
Energy Metabolism | 1 | 2007 | 50 | 0.020 |
Why?
|
Maternal-Fetal Exchange | 1 | 2007 | 13 | 0.020 |
Why?
|
Information Systems | 2 | 1997 | 23 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 19 | 0.020 |
Why?
|
Fetal Diseases | 1 | 2006 | 8 | 0.020 |
Why?
|
Tetracyclines | 1 | 2006 | 2 | 0.020 |
Why?
|
Rosacea | 1 | 2006 | 3 | 0.020 |
Why?
|
Macrolides | 1 | 2006 | 8 | 0.020 |
Why?
|
Acne Vulgaris | 1 | 2006 | 8 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2007 | 42 | 0.020 |
Why?
|
Infant, Newborn, Diseases | 1 | 2006 | 34 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2006 | 65 | 0.020 |
Why?
|
Capecitabine | 1 | 2006 | 2 | 0.020 |
Why?
|
Contraindications | 1 | 2006 | 15 | 0.020 |
Why?
|
Fluorouracil | 1 | 2006 | 12 | 0.020 |
Why?
|
Risk-Taking | 1 | 2006 | 109 | 0.020 |
Why?
|
Walking | 1 | 2006 | 87 | 0.020 |
Why?
|
Emergency Service, Hospital | 2 | 1999 | 382 | 0.020 |
Why?
|
Benzothiadiazines | 1 | 2004 | 2 | 0.020 |
Why?
|
Syndrome | 2 | 1996 | 29 | 0.020 |
Why?
|
Accident Prevention | 1 | 2004 | 3 | 0.020 |
Why?
|
Behavior | 1 | 2004 | 18 | 0.020 |
Why?
|
Posture | 1 | 2004 | 4 | 0.010 |
Why?
|
Vision Disorders | 1 | 2004 | 18 | 0.010 |
Why?
|
State Health Plans | 1 | 2004 | 44 | 0.010 |
Why?
|
Family Practice | 1 | 2004 | 53 | 0.010 |
Why?
|
Biomechanical Phenomena | 1 | 2004 | 3 | 0.010 |
Why?
|
Adrenergic beta-Agonists | 1 | 2004 | 33 | 0.010 |
Why?
|
Humeral Fractures | 1 | 2003 | 2 | 0.010 |
Why?
|
Religion | 1 | 2003 | 14 | 0.010 |
Why?
|
Particle Size | 1 | 2002 | 4 | 0.010 |
Why?
|
Amiodarone | 1 | 2002 | 2 | 0.010 |
Why?
|
Vehicle Emissions | 1 | 2002 | 23 | 0.010 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2002 | 12 | 0.010 |
Why?
|
Heart Arrest | 1 | 2002 | 32 | 0.010 |
Why?
|
Defibrillators, Implantable | 1 | 2002 | 32 | 0.010 |
Why?
|
Statistics as Topic | 2 | 1993 | 66 | 0.010 |
Why?
|
Employment | 1 | 2002 | 48 | 0.010 |
Why?
|
Poliovirus Vaccine, Oral | 1 | 2001 | 4 | 0.010 |
Why?
|
Immunity | 1 | 2001 | 6 | 0.010 |
Why?
|
Consumer Behavior | 1 | 2001 | 30 | 0.010 |
Why?
|
Poverty | 1 | 2002 | 182 | 0.010 |
Why?
|
Quality Indicators, Health Care | 1 | 2002 | 197 | 0.010 |
Why?
|
Least-Squares Analysis | 1 | 2000 | 16 | 0.010 |
Why?
|
Models, Econometric | 1 | 2000 | 11 | 0.010 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2001 | 95 | 0.010 |
Why?
|
Health Policy | 1 | 2001 | 136 | 0.010 |
Why?
|
Radioimmunoassay | 1 | 1999 | 5 | 0.010 |
Why?
|
Trust | 1 | 1999 | 31 | 0.010 |
Why?
|
Body Height | 1 | 1999 | 62 | 0.010 |
Why?
|
Progesterone Congeners | 1 | 1998 | 5 | 0.010 |
Why?
|
Cocaine-Related Disorders | 1 | 1998 | 5 | 0.010 |
Why?
|
Minnesota | 1 | 1998 | 54 | 0.010 |
Why?
|
Medical History Taking | 1 | 1998 | 37 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2001 | 333 | 0.010 |
Why?
|
Drug Implants | 1 | 1998 | 2 | 0.010 |
Why?
|
Hemodynamics | 1 | 1998 | 7 | 0.010 |
Why?
|
Cerebral Infarction | 1 | 1998 | 6 | 0.010 |
Why?
|
Uterine Cervical Neoplasms | 1 | 1999 | 127 | 0.010 |
Why?
|
Beverages | 1 | 1998 | 17 | 0.010 |
Why?
|
Urban Population | 1 | 1998 | 124 | 0.010 |
Why?
|
Ischemic Attack, Transient | 1 | 1998 | 28 | 0.010 |
Why?
|
Laundering | 1 | 1997 | 2 | 0.010 |
Why?
|
Bedding and Linens | 1 | 1997 | 4 | 0.010 |
Why?
|
Nebulizers and Vaporizers | 1 | 1997 | 7 | 0.010 |
Why?
|
Writing | 1 | 1997 | 12 | 0.010 |
Why?
|
Health Priorities | 1 | 1997 | 28 | 0.010 |
Why?
|
Patient Care Planning | 1 | 1997 | 51 | 0.010 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 1997 | 12 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 1998 | 270 | 0.010 |
Why?
|
Family | 1 | 1998 | 120 | 0.010 |
Why?
|
Cohort Effect | 1 | 1996 | 4 | 0.010 |
Why?
|
Sampling Studies | 1 | 1996 | 55 | 0.010 |
Why?
|
Fluid Therapy | 1 | 1996 | 11 | 0.010 |
Why?
|
Simplexvirus | 1 | 1996 | 2 | 0.010 |
Why?
|
Intensive Care, Neonatal | 1 | 1996 | 5 | 0.010 |
Why?
|
Death Certificates | 1 | 1996 | 19 | 0.010 |
Why?
|
Infant Mortality | 1 | 1996 | 22 | 0.010 |
Why?
|
Intensive Care Units, Neonatal | 1 | 1996 | 41 | 0.010 |
Why?
|
Physical Examination | 1 | 1995 | 21 | 0.010 |
Why?
|
Hematuria | 1 | 1995 | 7 | 0.010 |
Why?
|
Glucose | 1 | 1993 | 30 | 0.010 |
Why?
|
Insurance, Major Medical | 1 | 1992 | 1 | 0.010 |
Why?
|
Random Allocation | 1 | 1992 | 41 | 0.010 |
Why?
|
Reoperation | 1 | 1992 | 30 | 0.010 |
Why?
|
Selection Bias | 1 | 1991 | 24 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1991 | 35 | 0.010 |
Why?
|
Rectum | 1 | 1991 | 12 | 0.010 |
Why?
|
Personality Inventory | 1 | 1990 | 14 | 0.010 |
Why?
|
Group Practice, Prepaid | 1 | 1990 | 9 | 0.010 |
Why?
|
Life Tables | 1 | 1990 | 11 | 0.010 |
Why?
|
Computer Systems | 1 | 1988 | 3 | 0.000 |
Why?
|